Location:
Faculty Hall
Dear All,
—————————————————————
*CBR LECTURE SERIES*
*SHARVAREE GOKHALE MEMORIAL LECTURE*
Centre for Brain Research (CBR), IISc
—————————————————————–
Speaker: Steven E. Hyman, MD
Director, Stanley Center for Psychiatric Research and Core Member, Broad Institute of MIT and Harvard.
Date: September 19, 2018 (Wednesday) Time: 4.00 PM
Tea will be served following the talk
Venue: Faculty Hall, IISc
Title: Insight into Mental Illness from New Technology—and the Road Ahead
Abstract:
Schizophrenia, mood and anxiety disorders, and other forms of mental illness create enormous burdens for sufferers, families, and society. Despite these burdens, development of new treatments has been very slow because the human brain is remarkably complex, cannot be directly examined in life, and differs significantly from the brains of laboratory animals. During the last decade, human genetic studies made possible by advances in DNA technologies and computing have begun to yield clues to the molecular causes of mental illness. New biological technologies, including stem cellbased human neuronal models and advances in genome engineering, are aiding in deciphering genetic clues. I will focus on schizophrenia to show how far we have come in the last decade, and the difficult journey that lies ahead for the discovery of new treatments.
Brief Bio:
Steven E. Hyman, MD, is Harvard University Distinguished Service Professor of Stem Cell and Regenerative Biology, a Core Member of the Broad Institute of MIT and Harvard and Director of the Stanley Center for Psychiatric Research at the Broad. From 2001 to 2011, Hyman served as Provost of Harvard University, the university’s chief academic officer. As Provost, he had a special focus on establishment of collaborative initiatives in the sciences and engineering spanning multiple disciplines and institutions. From 1996 to 2001, he served as Director of the U.S. National Institute of Mental Health (NIMH), where he emphasized investment in neuroscience and emerging genetic technologies and also initiated a series of large practical clinical trials that were a forerunner of comparative efficacy studies. Hyman is President of the American College of Neuropsychopharmacology (2018), past President of the Society for Neuroscience (2015) the leading global association of neuroscientists, was founding President of the International Neuroethics Society (2008-2014) and served as Editor of the Annual Review of Neuroscience (2002-2016). He is a member of the U.S. National Academy of Medicine where he served on the governing Council (2012-2018). For the National Academies of Sciences, Engineering, and Medicine (NASEM), he has chaired the Forum on Neuroscience and Nervous System Disorders (2012-2018), which brings together industry, government, academia, foundations, and patient groups, and serves on the Governing Board of the National Research Council, the operating arm of NASEM. Hyman is a fellow of the American Academy of Arts and Sciences, the American Association for the Advancement of Science, and Distinguished Life Fellow of the American Psychiatric Association. In 2016, he was awarded the Rhoda and Bernard Sarnat International Prize in Mental Health by the National Academy of Medicine. He received his BA, summa cum laude, from Yale College, an MA from the University of Cambridge, which he attended as a Mellon fellow studying History and Philosophy of Science, and an MD, cum laude, from Harvard Medical School.
—————————————–
***All are cordially invited ***
